National Cancer Institute; Notice of Meeting, 40133 [06-6204]

Download as PDF Federal Register / Vol. 71, No. 135 / Friday, July 14, 2006 / Notices jlentini on PROD1PC65 with NOTICES time ranging from hours to weeks. This technology is an improvement of the microbead technology described in U.S. Patent No. 5,759,582. Applications: This technology has two commercial applications. The first is a pharmaceutical drug delivery application. The bead allows the incorporated protein or drug to be delivered locally at high concentration, ensuring that therapeutic levels are reached at the target site while reducing side effects by keeping systemic concentration low. This microbead accomplishes this while protecting the biologically active protein from harsh conditions traditionally encountered during microbead formation/drug formulation. The microbeads are inert, biodegradable, and allow a sustained release or multiple-release profile of treatment with various active agents without major side effects. In addition, the bead maintains functionality under physiological conditions. Second, the microbead and microparticles can be used in various research assays, such as isolation and separation assays, to bind target proteins from biological samples. A disadvantage of the conventional methods is that the proteins become denatured. The denaturation results in incorrect binding studies or inappropriate binding complexes being formed. The instant technology corrects this disadvantage by using a bead created in a more neutral pH environment. it is the same environment that is used for the finding of the protein of interest as well. Inventor: Phillip F. Heller (NIA). Patent Status: U.S. Provisional Application No. 60/602,651 filed 19 Aug 2004 (HHS Reference No. E–116– 2004/0–US–01); PCT Application No. PCT/US2005/026257 filed 25 Jul 2005, which published as WO 2006/023207 on 02 Mar 2006 (HHS Reference No. E– 116–2004/0–PCF–02). Licensing Status: Available for nonexclusive or exclusive licensing. Licensing Contact: Susan O. Ano, Ph.D.; 301–435–5515; anos@mail.nih.gov. Methods and Compositions Related to GHS–R Antagonist Description of Technology: This invention describes that additional functional role for D–Lys3 GHRP–6 (a known GHS–R antagonist, peptide) as a blocker of two well-known chemokine receptors, namely CCR5 and CXCR4. These receptors are major HIV coreceptors and are critical for HIV binding, fusion and entry into human T cells, monocytes, dendritic cells, and various other cells within the body. VerDate Aug<31>2005 17:44 Jul 13, 2006 Jkt 208001 Moreover, these receptors and their ligands play a major role in inflammation and a variety of acute and chronic disease states. Overall, these two mammalian chemokine receptors are currently major drug targets for treatment of AIDS, cancer and many immunoregulatory disorders. Many identified antogonists block one or the other receptor. Since D–Lys3 GHRP–6 actually binds and blocks both these chemokines receptors at the same time hindering their activity and HIV infectivity, D–Lys3 GHRP–6 may be a good therapeutic candidate for treatment of AIDS and inflammatory diseases. Inventors: Vishwa D. Dixit and Dennis D. Taub (NIA). Patent Status: U.S. Provisional application No. 60/773,076 filed 13 Feb 2006 (HHS Reference No. E–017–2004/ 0–US–01). Licensing Status: Available for nonexclusive or exclusive licensing. Licensing Contact: Sally Hu, Ph.D., M.B.A.; 301–435–5605; hus@od.nih.gov. Collaborative Research Opportunity: The National Institute on Aging’s Laboratory of Immunology is seeking statements of capability or interest from parties interested in collaborative research to further develop, evaluate, or commercialize this technology. Please contact Nicole D. Guyton at 301–435– 3101 or darackn@mail.nih.gov for more information. Dated: July 3, 2006 David R. Sadowski, Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health. [FR Doc. 06–6211 Filed 7–13–06; 8:45 am] 40133 Name of Committee: Advisory Committee to the Director, National Cancer Institute. Date: August 9, 2006 Time: 1 p.m. to 2 p.m. Agenda: Review of Adolescent and Young Adult Oncology Progress Review Group Report. Place: National Institutes of Health, Building 31, Room 11A48, 31 Center Drive, Bethesda, MD 20892, (Telephone Conference Call). Contact Person: Cherie Nichols, Director of Science Planning and Assessment, National Cancer Institute, Building 6116, Room 205, Bethesda, MD 20892, (301) 496–5515. Any interested person may file written comments with the committee by forwarding the statement to the Contact Person listed on this notice. The statement should include the name, address, telephone number and when applicable, the business or professional affiliation of the interested person. Information is also available on the Institute’s home page: deainfo.nci.nih.gov/ advisory/joint/htm, where an agenda and any additional information for the meeting will be posted when available. (Catalogue of Federal Domestic Assistance Program Nos. 93.392, Cancer Construction; 93.393, Cancer Cause and Prevention Research; 93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer Control, National Institutes of Health, HHS). Dated: July 7, 2006. Anna Snouffer, Acting Director, Office of Federal advisory Committee Policy. [FR Doc. 06–6204 Filed 7–13–06; 8:45 am] BILLING CODE 4140–01–M DEPARTMENT OF HEALTH AND HUMAN SERVICES BILLING CODE 4140–01–M National Institutes of Health DEPARTMENT OF HEALTH AND HUMAN SERVICES National Cancer Institute; Notice of Closed Meeting National Institutes Health Pursuant to section 10(d) of the Federal Advisory Committee Act, as amended (5 U.S.C. Appendix 2), notice is hereby given of the following meeting. The meeting will be closed to the public in accordance with the provisions set forth in sections 552b(c)(4) and 552b(c)(6), Title 5 U.S.C., as amended. The grant applications and the discussions could disclose confidential trade secrets or commercial property such as patentable material, and personal information concerning individuals associated with the grant applications, the disclosure of which could constitute a clearly unwarranted invasion of personal privacy. National Cancer Institute; Notice of Meeting Pursuant to section 10(a) of the Federal Advisory Committee Act, as amended (5 U.S.C. appendix 2), notice is hereby given of a meeting of the Advisory Committee to the Director, National Cancer Institute. The meeting will be open to the public, with attendance limited to space available. Individuals who plan to attend and need special assistance, such as sign language interpretation or other reasonable accommodations, should notify the Contact Person listed below in advance of the meeting. PO 00000 Frm 00073 Fmt 4703 Sfmt 4703 E:\FR\FM\14JYN1.SGM 14JYN1

Agencies

[Federal Register Volume 71, Number 135 (Friday, July 14, 2006)]
[Notices]
[Page 40133]
From the Federal Register Online via the Government Printing Office [www.gpo.gov]
[FR Doc No: 06-6204]


-----------------------------------------------------------------------

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes Health


National Cancer Institute; Notice of Meeting

    Pursuant to section 10(a) of the Federal Advisory Committee Act, as 
amended (5 U.S.C. appendix 2), notice is hereby given of a meeting of 
the Advisory Committee to the Director, National Cancer Institute.
    The meeting will be open to the public, with attendance limited to 
space available. Individuals who plan to attend and need special 
assistance, such as sign language interpretation or other reasonable 
accommodations, should notify the Contact Person listed below in 
advance of the meeting.

    Name of Committee: Advisory Committee to the Director, National 
Cancer Institute.
    Date: August 9, 2006
    Time: 1 p.m. to 2 p.m.
    Agenda: Review of Adolescent and Young Adult Oncology Progress 
Review Group Report.
    Place: National Institutes of Health, Building 31, Room 11A48, 
31 Center Drive, Bethesda, MD 20892, (Telephone Conference Call).
    Contact Person: Cherie Nichols, Director of Science Planning and 
Assessment, National Cancer Institute, Building 6116, Room 205, 
Bethesda, MD 20892, (301) 496-5515.
    Any interested person may file written comments with the 
committee by forwarding the statement to the Contact Person listed 
on this notice. The statement should include the name, address, 
telephone number and when applicable, the business or professional 
affiliation of the interested person.
    Information is also available on the Institute's home page: 
deainfo.nci.nih.gov/advisory/joint/htm, where an agenda and any 
additional information for the meeting will be posted when 
available.

(Catalogue of Federal Domestic Assistance Program Nos. 93.392, 
Cancer Construction; 93.393, Cancer Cause and Prevention Research; 
93.394, Cancer Detection and Diagnosis Research; 93.395, Cancer 
Treatment Research; 93.396, Cancer Biology Research; 93.397, Cancer 
Centers Support; 93.398, Cancer Research Manpower; 93.399, Cancer 
Control, National Institutes of Health, HHS).

    Dated: July 7, 2006.
Anna Snouffer,
Acting Director, Office of Federal advisory Committee Policy.
[FR Doc. 06-6204 Filed 7-13-06; 8:45 am]
BILLING CODE 4140-01-M

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.